Semaglutide shows potential for treating Alzheimer's symptoms

Scientists are exploring new treatments for Alzheimer's disease. A recent study suggests that semaglutide, a drug commonly used for diabetes and weight loss, may help ease some symptoms of Alzheimer's. The research, conducted in China, involved mouse models of Alzheimer's disease. Semaglutide is sold under brand names like Ozempic and Wegovy. The findings show that the drug could help change immune cells in the brain to a more protective state. This change may slow down or prevent the progression of Alzheimer's. In the study, mice with Alzheimer's showed improvements after being treated with semaglutide for one month. The drug decreased amyloid-beta protein buildup in the brain, which is harmful in Alzheimer's patients. The treated mice also performed better in memory tests, showing improvements close to those of healthy mice. Researchers observed more benefits too. Semaglutide reduced inflammatory molecules in the brain and increased those with anti-inflammatory effects. This is important because inflammation can damage the brains of Alzheimer's patients. The study found that some immune cells, called microglia, shifted from a harmful state to a more neutral one after treatment with semaglutide. The scientists believe that semaglutide's anti-inflammatory effects contribute to its potential in protecting against Alzheimer's. They note that while previous studies have hinted at this potential link, more research is needed to confirm these findings and understand how the drug works. While these promising results have been seen in mice, scientists are beginning trials to test semaglutide in humans with Alzheimer's. This gives hope to many individuals living with the disease, as well as those at risk. The research has been published in the journal Neuroscience.